Bisphosphonates: Do we know their role in adjuvant breast cancer treatment?

ONCOLOGY

Volumn 24, Issue 6, 2010, Pages

  Barginear, Myra F ^a   Van Poznak, Catherine ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; IBANDRONIC ACID; RISEDRONIC ACID; ZOLEDRONIC ACID;

BONE MASS; BREAST CANCER; CANCER SURVIVAL; CLINICAL TRIAL; FRAGILITY FRACTURE; HUMAN; JAW OSTEONECROSIS; NOTE; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; RISK ASSESSMENT;

EID: 77954172234     PISSN: 08909091     EISSN: 08909091     Source Type: Journal    
DOI: None     Document Type: Note

References (16)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2008. CA Cancer J Clin 58:71-96, 2008.
2. American Cancer Society: Breast Cancer Facts & Figures 2007-2008. Available at: http://www.cancer.org/downloads/STT/BCFF-Final.pdf. Accessed on April 20, 2010.
3. Lin NU, Winer EP: Advances in adjuvant endocrine therapy for postmenopausal women. J Clin Oncol 26:798-805, 2008. (Pubitemid 351264393)
4. Shapiro CL, Manola J, Leboff M: Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 19:3306-3311, 2001. (Pubitemid 32642182)
5. Gralow JR, Biermann JS, Farooki A, et al,: NCCN task force report: Bone health in cancer care. J Natl Compr Canc Netw 7 (Suppl 3):S1-S32, 2009.
6. Reeder JG, Brufsky AM: The role of bisphosphonates in the adjuvant setting for breast cancer. Oncology (Williston Park) 24:462-467, 475, 2010.
7. Brown JE, Ellis SP, Lester JE, et al: Prolonged efficacy of a single dose of the bisphosphonate zoledronic acid. Clin Cancer Res 13:5406-5410, 2007. (Pubitemid 47510367)
8. Grey A, Bolland MJ, Wattie D, et al: The antiresorptive effects of a single dose of zoledronate persist for two years: A randomized, placebo-controlled trial in osteopenic postmenopausal women. J Clin Endocrinol Metab 94:538-544, 2009.
9. Gnant M, Mlineritsch B, Luschin-Ebengreuth G, et al: Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 9:840-849, 2008.
10. Brufsky AM, Bosserman LD, Caradonna RR, et al: Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer 9:77-85, 2009.
11. Shapiro CL, Halabi S, Gibson G, et al: Effect of zoledronic acid on bone mineral density (BMD) in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: First results from CALGB trial 79809 (abstract 512). J Clin Oncol 26:,2008.
12. Burkinshaw R, Winter M, Thorpe H, et al: Osteonecrosis of the jaw and dental related adverse events during adjuvant therapy for early breast cancer: Initial dental safety findings from the AZURE study Cancer Treatment Reviews. 34(suppl 1):40-41, 2008.
13. Lester JE, Dodwell D, Purohit OP, et al: Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res 14:6336-6342, 2008.
14. Van Poznak C, Hannon RA, Mackey JR, et al: Prevention of aromatase inhibitor-induced bone loss using risedronate: The SABRE trial. J Clin Oncol 28:967-975, 2010.
15. Bock O, Felsenberg D: Bisphosphonates in the management of postmenopausal osteoporosis optimizing efficacy in clinical practice. Clin Interv Aging 3:279-297, 2008. (Pubitemid 352037868)
16. Hines SL, Mincey BA, Sloan JA, et al: Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer. J Clin Oncol 27:1047-1053, 2009.